Abstract:Signal transducers and activators of transcription (STATs) are a family of transcription factors involved in the regulation of early embryonic development, immune response, cell proliferation, differentiation, and apoptosis. Particularly, STAT3 regulates lobuloalveolar apoptosis during involution in mammary gland development, and its activation is required for the growth of CD44+CD24- stem cell-like breast cancer cells and the development of multiple cancers including breast cancer. Increased STAT3 transcriptional activity was found to correlate with ER-negative phenotype in breast cancer cell lines and in primary human invasive ductal breast carcinomas. Thus, STAT3 represents a promising target for therapeutic and preventive intervention of breast cancer. Yet current strategies of inhibiting STAT3 activity did not sufficiently block STAT3 activation in cancer cells due to their limited potency, poor solubility or bioavailability. Despite several STAT3 inhibitors have been advanced into early clinical trials, there is an urgent need to develop a more successful strategy targeting STAT3 for cancer therapies, and preventive use in particular. We attempted to identify potent and orally active STAT3 inhibitors for such purposes and have designed, synthesized and screened a series of novel STAT3 inhibitors utilizing fragment-based drug design strategy. A number of small molecules with new scaffolds have been discovered with low-micromolar to nanomolar potency in inhibiting the proliferation of various human breast cancer and pancreatic cancer cells. The identified compound HJC0152 significantly suppresses basal and IL-6-stimulated STAT3 promoter activity and STAT3 phosphorylation, reduces total STAT3 protein expression, induces G2/M cell cycle arrest, and induces early apoptosis. HJC0152 has demonstrated a better potency in suppressing the growth of MDA-MB-231 breast xenograft tumors via intraperitoneal and oral administrative routes, with remarkably improved aqueous solubility (3,300 fold improvement) and less toxicity than the lead compounds. In conclusion, we have developed a new class of orally active STAT3 inhibitors with superior drug-like properties for further preclinical therapeutic and preventive evaluation. Citation Format: Zhengduo Yang, Haijun Chen, Lili Chu, Yusong Zhang, Chunyong Ding, Kristin Terry, Jia Zhou, Qiang Shen. Developing novel STAT3 inhibitors for the treatment and prevention of cancer. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr B63.

Allosteric inhibitors of the STAT3 signaling pathway

Research Progress of STAT3-based Dual Inhibitors for Cancer Therapy.

Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation

Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives

Small Molecular Inhibitors and Degraders Targeting STAT3 for Cancer Therapy: an Updated Review (from 2022 to 2024)

Revisiting Signal Transducer and Activator of Transcription 3 (STAT3) As an Anticancer Target and Its Inhibitor Discovery: Where Are We and Where Should We Go?

Novel activators and small-molecule inhibitors of STAT3 in cancer

Structure, Function, Signaling Pathways and Clinical Therapeutics: the Translational Potential of STAT3 As a Target for Cancer Therapy

Small Molecule Inhibitors of STAT3 for Cancer Therapy

Targeting STAT3 in Cancer Immunotherapy

Small-molecule Inhibitors Targeting the DNA-binding Domain of STAT3 Suppress Tumor Growth, Metastasis and STAT3 Target Gene Expression in Vivo

Targeting the transcriptional activity of STAT3 by a novel fusion protein

Novel inhibitors of the STAT3 signaling pathway: an updated patent review (2014-present)

Allosteric Communication Across STAT3 Domains Associated with STAT3 Function and Disease-Causing Mutation.

STAT3 Pathway in Cancers: Past, Present, and Future.

Targeted Inhibition of STAT3 As a Potential Treatment Strategy for Atherosclerosis.

Multiple regulation pathways and pivotal biological functions of STAT3 in cancer

Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation

Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

Abstract B63: Developing Novel STAT3 Inhibitors for the Treatment and Prevention of Cancer

A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3